Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
CAMBRIDGE, Mass., January 15, 2007 /PRNewswire/ -- Genzyme Corporation announced today that a research study published in the January issue of the Journal of Bone and Mineral Research demonstrates that long-term use of Cerezyme(R) (imiglucerase for injection) significantly improves bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner.
Cerezyme, an enzyme replacement therapy, is the standard of care for patients with Type 1 Gaucher disease. Patients with Gaucher disease are at increased risk for developing bone complications, including osteopenia, osteoporosis and fractures. To evaluate the effect of long-term Cerezyme use on bone mineral density, the investigators conducted the largest-ever retrospective analysis of more than 500 patients participating in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. The ICGG Gaucher Registry has been sponsored by Genzyme since 1991 and is overseen by an international board of scientific advisors.
The study compared the outcomes of 342 patients with Type 1 Gaucher disease who received treatment with Cerezyme to 160 patients who did not receive treatment. Both the treated and untreated patients had bone mineral density values significantly below normal at baseline. The patients who received Cerezyme were dosed at a range from 15-60 units per kilogram of body weight administered every two weeks. Bone mineral density was assessed by dual energy x-ray absorptiometry (DXA) of the lumbar spine.
The analysis found that patients receiving Cerezyme experienced a significant increase in bone mineral density over time when compared with patients who were not treated. Furthermore, the improvements in bone mineral density were found to be dose-dependent, with those patients receiving higher doses of Cerezyme achieving greater increases in bone mineral density. On average, the patients receiving Cerezyme at 60 units per kilogram biweekly achieved scores that approached those in the general population, whereas the untreated patients experienced no improvement or declining bone mineral density over the same period.
The investigators found that achieving normal (age- and sex-adjusted) bone mineral density scores may require eight years or more of sustained treatment with Cerezyme, longer than is required to reach normal values for other disease parameters, such as hematological parameters or reductions in liver and spleen volume. They conclude that a normal bone mineral density score should be a therapeutic goal for patients with Type 1 Gaucher disease.
Cerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly. Important Safety Information: Adverse reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling, and sterile abscess at the site of venipuncture. Symptoms suggestive of hypersensitivity include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Approximately 15% of patients have developed IgG antibodies; periodic monitoring is suggested. Side effects should be reported promptly to Genzyme Medical Affairs at 800-745-4447, option 2. Cerezyme is available by prescription only.
Please see full prescribing information available on www.cerezyme.com.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.
Genzyme(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.
Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.
Media Contact: Investor Contact: Dan Quinn Sally Curley (617) 768-6849 (617) 768-6140
CONTACT: Media, Dan Quinn, +1-617-768-6849, or Investors, Sally Curley,+1-617-768-6140, both of Genzyme Corporation
Company News On-Call: http://www.prnewswire.com/comp/113803.html
Company News On-Call: http://www.prnewswire.com/comp/104284.html /
Ticker Symbol: (NASDAQ-NMS:GENZ)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: January 2007
Recommended for you